Skip to main content

Mupirocin

FDA recalls

2 rows

DateCompany and reasonClass
Aug 29, 2024Glenmark Pharmaceuticals Inc., USA
Subpotent Drug
Class II · Completed
Apr 12, 2022McKesson Medical-Surgical Inc. Corporate Office
cGMP deviations: Temperature abuse
Class II · Terminated

← Back to Mupirocin

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).